AstraZeneca and Swiss Cancer Institute Support Groundbreaking Oncology Projects with CHF 30,000
27.04.2026 | from AstraZeneca AG
Reading time: 3 minutes
27.04.2026, AstraZeneca Switzerland and the Swiss Cancer Institute jointly launch the 'Transform Care Award'. With a prize of CHF 30,000, the award promotes innovative projects that sustainably improve oncological and hematological care in Switzerland. The aim is to support solutions that make a tangible difference for those affected, strengthen the healthcare system, and bring about systemic improvements – from early detection to aftercare.
Cancer care faces major challenges that can only be addressed through interdisciplinary collaboration and groundbreaking approaches. To promote such initiatives, AstraZeneca Switzerland and the Swiss Cancer Institute (SCI) have introduced the 'Transform Care Award'. This award targets medical professionals, researchers, start-ups, and non-profit organizations that actively reshape patient care with their projects.
Targeted support for tangible change
The award focuses on initiatives that achieve sustainable impact by, for example:
accelerating early detection and diagnosis
ensuring guideline-compliant treatment
making care pathways more seamless for everyone involved
having a scalable impact on the entire health system
A joint commitment to strengthening the system
'Our partnership with the Swiss Cancer Institute combines expertise from pharmaceutical research and clinical practice,' says Ignacio Dolado, Medical Affairs Head Oncology at AstraZeneca Switzerland. Stephanie Pavlovic, Senior Event Manager at the Swiss Cancer Institute, adds: 'Together, we want to support innovations that sustainably strengthen the Swiss healthcare system to the benefit of patients.'
Further information about the award and the conditions of participation can be found at: https://www.swisscancerinstitute.ch/en/researchers/awards-fellowships/swiss-cancer- instituteastrazeneca-transform-care-award/
Swiss Cancer Institute
The Swiss Cancer Institute is the central network for clinical cancer research in Switzerland and a research institution of national importance (Art. 15 FIFG). It includes all university hospitals as well as the leading cantonal, regional, and private hospitals of the country. Since 1965, we have been dedicated as a non-profit organization to continuously improving cancer treatment in Switzerland. Guided by our vision 'Clinical Research for a Cure Tomorrow,' around 950 researchers conduct clinical studies on all types of cancer. We are also a central point of contact for authorities, professional associations, and the pharmaceutical industry. Around 70 employees at our headquarters in Bern work closely with Switzerland's leading oncology clinics.
For more information about the Swiss Cancer Institute: https://www.swisscancerinstitute.ch
Media contact:
Tel. +41 (0) 41 725 75 75; media.switzerland@astrazeneca.com
Barbara Hess, Corporate Communications Lead, AstraZeneca Switzerland
Editor's note: Image rights belong to the respective publisher.
Conclusion of this article: « AstraZeneca and Swiss Cancer Institute Support Groundbreaking Oncology Projects with CHF 30,000 »
AstraZeneca AG
We are a global, innovative biopharmaceutical company specializing in the research, development, manufacturing, and marketing of prescription medications. AstraZeneca thus makes a significant contribution to patient health.
Our activities center on science and patients. Our focus lies on those therapeutic areas where we believe we can make the most valuable contribution.
Our headquarters is located in London. AstraZeneca employs approximately 50,000 people worldwide.
We conduct research and development activities on three continents and invest over USD 4 billion annually in these areas. Our revenue was USD 28 billion in 2012.
Note: The "About Us" text is taken from public sources or from the company profile on HELP.ch.
Source: AstraZeneca AG, Press release
Original article published on: AstraZeneca und Swiss Cancer Institute fördern wegweisende Projekte in der Onkologie mit CHF 30‘000